Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-PrEP: Raltegravir +/- Lamivudine for HIV Prevention
NCT03205566Phase 4Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Level of Raltegravir Alone or Raltegravir/Lamivudine Required for 100% ex Vivo Protection. Started Sep 2017; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03205566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205566.